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PREFACE  
“Drugs Don't Work in Patients who don’t take them” (C. Everett Koop) 
Medication adherence continues to be a vital factor contributing towards the achievement of 
patient treatment goals.  This study was conducted to provide some insight into the medication 
adherence behaviour of private sector patients afflicted with communicable and non-
communicable chronic diseases. 
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ABSTRACT 
 
Background  
Medication adherence continues to be a vital factor contributing towards the achievement of 
treatment goals in patients with chronic diseases. There is a sparse amount of data available on 
the adherence behaviour and the types of medications used in private sector patients with 
communicable and non-communicable diseases in South Africa but this is limited and dated. 
This study was directed at providing information on the medication adherence rates of such 
patients and the factors that influence such behaviour.  
 
Aim and Objectives 
To investigate the medication adherence behaviour of patients suffering from non-
communicable and communicable diseases in the private health care sector of the eThekwini 
Municipality of KwaZulu-Natal and to describe the reasons for such behaviour.  
 
Methods  
A self-reported anonymous medication adherence questionnaire was used to obtain data, from 
233 private sector patients afflicted with HIV, Type 2 Diabetes Mellitus, Hypertension and 
Dyslipidaemia in the eThekwini Municipality of KwaZulu-Natal. The questionnaire focused on 
the adherence behaviour of these participants and factors that influenced their adherence 
behaviour. Medication adherence was determined by the number of days of medication missed 
during the last 30 days. Data was collected and analysed using SPSS. 
 
Results  
Majority of participants were aged between 51-60 years (26.6%), and were of male gender 
(52.8%). An almost equal number of participants were afflicted with single disease (n=116) or 
multiple diseases (117). Hypertension was the most prevalent ailment (n=167), followed by 
Type 2 Diabetes (n=113), Dyslipidaemia (n=94) and HIV (n= 26). Over 62% of participants 
reported not missing any medication during the last 30 days. More than 21% had stated missing 
1-2 days of their medication and 15.9% reported missing 3 or more days of medication during 
the last 30 days. With regards to single ailment, the highest percentage of adherence was 
reported in participants afflicted with Hypertension (60.6%), and Type 2 diabetes (58.3%). HIV 
and Dyslipidaemia had the lowest rates of adherence as 45% (n=9) of HIV only and 57.1% 
(n=4) of Dyslipidaemia only afflicted participants reported missing 1 or more days of their 
medication. The highest rate of non-adherence was found amongst the age group of participants 
51-60 years old, while the highest rate of adherence was found in the group aged 70 years+. 
Reasons for non-adherence included cost, forgetting to take medication, running out of 
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medication, stopping medication because it made them feel worse or gave a side effect and 
having difficulty with time schedules or having medication with/without food.   
 
Conclusion 
Participants afflicted with communicable and non-communicable diseases in the private health 
care sector have sub-optimal medication adherence. Although no significant correlations were 
found between having a particular disease and the rate of adherence, participants afflicted with 
HIV and Dyslipidaemia alone were the least adherent to their medication. Reasons for their non-
adherence were similar to other studies reported. 
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CHAPTER 1 
 
1. INTRODUCTION 
 
  
1.1 Background and literature review 
South Africa is heavily burdened with both communicable and non-communicable diseases 
(NCD) 1, 2, 3.  Known as the country with the largest Human Immunodeficiency Virus (HIV) 
epidemic, South Africa was estimated to have 6.19 million people infected in 2015. This was a 
prevalence rate of approximately 11.2% of the total population 4, 5. Although great focus has 
been placed on the fight against HIV and Acquired Immunodeficiency Syndrome (AIDS), the 
Government has equally recognised the contributing burden of NCDs on the Health care system 
3 as it is occurring simultaneously with an ageing HIV-positive population 6. 
The World Health Organisation (WHO) estimated that in 2014, 43% of the total deaths in South 
Africa were due to NCDs 7.  In February 2016 the South African government introduced sin 
taxes on sweetened beverages in addition to ongoing taxes on alcohol and tobacco to discourage 
the population from participating in consumption of these unhealthy products. This is in line 
with governmental action world-wide, as such activities are linked to NCDs which cause 
tremendous financial strain on the health care system. The combined and growing burden of 
HIV/AIDS and NCD’s require an extraordinary response from the South African health care 
system 8 to treat these diseases and reduce the risk of the complications that ensue. Even though 
HIV is infectious in origin, it is a chronic condition that requires the same management as 
NCDs 9, 10. 
One method of tackling the growing burden of these diseases and preventing the complications 
that ensue is addressing the issue of medication adherence. Medication adherence has been 
defined as the extent to which patients take medications as prescribed by their health care 
providers 11, 12.  The rate of adherence is frequently described as a percentage of the prescribed 
doses of the medication taken over a specified period of time 10. Positive treatment outcomes 
have been associated with high adherence to prescribed medication regimens. Low or sub-
optimal adherence is associated with numerous shortcomings such as higher health care costs, 
increased hospitalisation rates and pre-mature deaths 13.  
It has been said that if adherence interventions were improved, this would add far more greatly 
to the health of the population than any advancement in medicinal treatment 9. The complete 
benefit of prescribed medications can only be achieved if patients abide to their medication 
therapies 12. However many patients experience difficulty in following prescribed regimens 9 
due to various reasons. Common reasons for not adhering to prescribed medication as identified 
in previous studies include: forgetfulness , other priorities , decision to omit , lack of 
understanding, complexity of regimen , side effects, costs and emotional factors 14,15,16.   
Medication adherence rates have been found to be higher in patients with acute ailments as it is 
easier to abide to prescribed regimens for shorter periods 12. Adherence rates may be low in 
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patients afflicted with asymptomatic conditions such as Hypertension, Diabetes, HIV and 
Dyslipidaemia as they do not experience physical symptoms of illness until the later stages of 
the disease 17. Previous studies have also revealed variable results on adherence rates in patients 
afflicted with communicable and non-communicable diseases. Coherence is that adherence rates 
are below optimal for patients with chronic ailments 9, 18,19,20,21. 
Numerous international studies have varying results with regards to adherence in patients with 
NCDs. For example, in the Heart and Soul Study (2000 and 2002), the risk of cardiovascular 
events associated with self-reported medication non-adherence were prospectively evaluated in 
1015 outpatients. Non-adherence was defined as taking medications as prescribed for 75% of 
the time or less.  Participants were asked a single question: “In the past month, how often did 
you take your medications as prescribed by the doctor?” Eighty three of 1015 patients (8.2%) 
where found to be non-adherent to their regimens, and 146 (14.4%) developed cardiovascular 
events. The authors concluded that self-reported medication non-adherence was linked with a 
greater than 2-fold increased rate of ensuing cardiovascular events 22. 
In another study conducted in Ontario in 2002 among elderly patients, 25% of patients 
prescribed a statin therapy for acute coronary syndrome or chronic coronary artery disease had 
discontinued their therapy at 6 months after initiation. Patients were evaluated on their 
medication adherence over two years and it was suggested that many patients initiating statin 
therapy may receive little or no benefit from statins because of early discontinuation 20. 
A Ugandan study conducted between the years 2012-2013 at two general hospitals (n=521) 
revealed that one in every five respondents did not adhere well to their diabetic medication 
(n=88). This was based on patients’ self-reports at an adherence index of 80%. Factors that 
contributed towards adherence included length of time on treatment, drug availability and 
receiving prior diabetic education.  Social demographic factors did not have any association 
with adherence rates in this study population 23.  
Local studies conducted at public health facilities have also revealed sub-optimal rates of 
medication adherence. Peltzer et al conducted a study in 2007 investigating the Anti-Retroviral 
Treatment (ART) adherence behaviour of patients from 3 public hospitals in KwaZulu-Natal.  
Five hundred and nineteen patients were interviewed on their adherence behaviour taking into 
consideration adherence to time, dose and food. The results revealed that 82.9% (n=427) of the 
participants where 95% adherent to their regimens using a 30 day visual analogue scale. About 
72.4% were adherent to the time advised to take their medication and 71.7% were adherent to 
taking their medication as prescribed with regards to food 24.  
Similar adherence rates were found in a chronic medication adherence survey, conducted by 
Mathevula in 2013 at the Waterberg District hospital. Three hundred and seven patients afflicted 
with communicable diseases such as HIV and NCDs such as Diabetes, and Hypertension were 
interviewed regarding their adherence to medication regimens. Patients with more than one 
chronic disease had the lowest adherence rate in this group. The highest rate of adherence was 
found in patients with HIV. The results were as follows:  81% of the respondents said they 
never missed to take their treatment as prescribed in the previous month. Forty two (21%) of the 
respondents taking Anti-Retroviral (ARV) drugs indicated that they missed a dose at least once 
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in the previous month. Fifteen (31%) of those on anti-hypertensives said they missed a dose in 
the previous month. Ten (28%) of those taking anti-diabetics had missed a dose in the previous 
month. Among those on both anti diabetics and anti-hypertensive’s, eight (34%) said they 
missed a dose in the previous month. Adherence was calculated as taking 95% and above of the 
prescribed medication for a period of one month 25.   
A literature search has revealed a paucity of studies in South Africa with regards to medication 
adherence in the private health care sector, particularly in patients with NCDs. To date no 
medication adherence studies investigating adherence rates in patients afflicted with NCDs were 
conducted in the private health care sector of South Africa. One study investigating the use of 
prescribed medication for common chronic ailments in patients who receive health care from 
both public and private health facilities in South Africa does exist, but this did not examine 
patients’ medication adherence rates 26. Only one self-reported adherence study investigating the 
medication adherence rates of private sector HIV patients was identified. This study was 
conducted by Naidoo in 2005 and investigated factors influencing Highly Active Antiretroviral 
Treatment (HAART) medication adherence in the private health care sector of eThekwini. This 
study revealed sub-optimal medication adherence rates of HIV patients as forty nine out of fifty 
five (89.1%) were non-adherent to their medication regimes. Non-adherence was regarded as 
missing one day or more of their therapy 15.  
Low adherence is of concern for patients with both communicable and non-communicable 
diseases as it increases the risk of complications, increases health care costs and may ultimately 
result in death 14. Poor adherence in communicable diseases like HIV is of extreme concern, as 
non-adherence leads to poor viral suppression, increased viral resistance, increased risk of 
opportunistic infections and treatment failure 27.  Although no consensual average compliance 
level has been designated to represent high or low adherence, numerous studies have used an 
adherence rate of greater than or equal to 80% as an indicator of optimal compliance or high 
adherence for NCDs 12, 14, 28. An adherence rate of no less than 95% is indicated for HIV as this 
is crucial for viral suppression and the deterrence of resistance and treatment failure 29. 
 
1.2 Core Research Problem and Clinical Significance 
International studies have produced immense data on the medication adherence behaviour of 
patients in both private and public health facilities, whilst local studies have focused and given 
more insight into the medication adherence behaviour of public sector patients with chronic 
ailments. There is a lack of data regarding the medication adherence behaviour of patients 
receiving care from the private health care sector in South Africa, especially in patients afflicted 
with communicable and non-communicable diseases. 
There is inadequate data regarding the following about patients receiving care from the private 
health care sector in KwaZulu-Natal such as: 
 The types of medications patients are prescribed 
 The factors affecting medication adherence 
 The level of adherence to prescribed therapies.  
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Thus a medication adherence survey was conducted by interviewing patients receiving care 
from private health care facilities in eThekwini using a questionnaire. The null hypothesis is that 
patients in the private health care sector adhere to their medication in both communicable and 
non-communicable diseases. 
 
1.3 Purpose of the study 
The main purpose of this study was to determine if medication adherence is a problem in private 
sector patients afflicted with communicable and non-communicable diseases. Four disease 
groups where investigated in this study namely HIV, a communicable disease in which South 
Africa has the largest epidemic, and the following three non-communicable diseases, Type 2 
Diabetes Mellitus, Hypertension and Dyslipidaemia. The latter three diseases are the highest 
prevalent chronic diseases insured by medical aid schemes according to Council of Medical 
Schemes (CMS) 30.  
 
1.4 Aims of the study 
The study aimed to achieve the following: 
To investigate the medication adherence of patients suffering from non-communicable 
and communicable diseases in the private health care sector of the eThekwini 
Municipality of KwaZulu-Natal whilst the, 
Secondary aim of the study was to determine if medication adherence differed amongst 
patients with communicable and non-communicable diseases such as Type 2 Diabetes 
Mellitus, Hypertension, Dyslipidaemia and HIV. 
 
1.5 Specific Objectives 
The following objectives were identified as goal points for this study: 
-To describe the demographic details of patients in the study. 
-To document the medical conditions that patients have. 
-To document the medication therapies patients are prescribed. 
-To determine patients’ adherence to medicine therapies. 
-To determine the factors influencing medication adherence and report any barriers to 
adherence that patients may experience 
-To determine if adherence rates differ amongst patients with different diseases. 
-To disseminate the information. 
 
1.6 Methodology 
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1.6.1 Study design 
This study was a cross sectional, analytical and descriptive study. Quantitative data was 
collected using a self-reported medication adherence questionnaire. Questions were closed 
ended to facilitate data collection and analysis. A self-reported medication adherence survey 
was chosen as the tool as it was easy to implement and not very costly to administer. 
1.6.2 Study population    
The study population consisted of patients who were receiving health care treatment from 
private sector doctors practising in the eThekwini Municipality of KwaZulu-Natal. Participants 
had to be afflicted with one or more of the following diseases: HIV, Type 2 Diabetes, 
Hypertension and Dyslipidaemia.  
 
1.6.3 Study period 
The study was conducted over a period of two months from 18 October 2017 – 18 December 
2017. Patients were interviewed while receiving care from various General Practitioners (GP) 
rooms across the eThekwini Municipality. 
 
1.6.4 Sampling strategy 
Study participants were recruited into the study via stratified sampling. Access to study 
participants was granted via the random and convenient sampling of doctors.  
A list of general practitioners was obtained from the med pages section of the yellow pages 
directory available in the eThekwini region. Doctors in the med pages of this book are separated 
according to speciality. The General practitioners details were transferred to a list from which 
doctors were then randomly selected to invite to participate. A letter (Appendix 3) was sent via 
email or fax to each of the doctors’ practices after telephonically contacting the rooms, 
informing them of the study, its aims and the data needed to be gathered from this study. The 
letter (Appendix 3) also requested permission from the practitioners to allow the researcher to 
meet patients receiving care at the practitioners practice. Only 5 doctors agreed to participate via 
this sampling method.  
Due to a lack of positive responses from doctors, with only 5 agreeing to participate, and the 
limited number of participants available to sample via randomly sampling, doctors were then 
conveniently asked to participate in this study. Nine doctors had agreed to participate via this 
method of convenient sampling. A total of 14 General practitioners agreed to participate in this 
study.  
After doctors had signed the consent form (Appendix 3), a time and date to randomly interview 
patients at their practices were agreed upon. Participants were randomly selected at each 
practice and interviewed after consenting to participate (See Appendix 4 for Patient Consent 
Form). Bias was avoided in the selection process as neither the doctor nor researcher had any 
influence over who chose to receive care on that particular day.  
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1.6.5 Statistical planning 
The study questionnaire used closed ended questions to extract information from participants 
regarding the following  
 Demographic Information 
o Age  
o Gender 
o Race 
o Level of education 
o Chronic disease diagnosis 
 Medication regimen 
o Prescribed medication usage  
o Self-medication usage  
 Adherence Behaviour 
o Reasons for taking medication 
o Reasons for not taking medication  
o Storage of medication  
o Number of missed pills 
 
1.6.6 Sample Size 
A sample size, representing the population of interest, was calculated after consulting with a 
statistician from the University of Kwa-Zulu Natal. A between –subjects ANOVA was used to 
determine the sample size of the study population. The total sample was distributed among 4 
disease groups, namely patients afflicted with Type 2 Diabetes, Hypertension, Dyslipidaemia 
and HIV. 
The following was used to determine the sample size: 
1. Effect size: 0.25 (medium strength of phenomenon)  
2. Type 1 error: 0.05 (Recommended for medical studies) 
3. Type 2 error: 0.2 (Recommended for medical studies) 
4. Power: 0.80  
5. Critical F value: 2.655 (value which F should be over to get a 
significant result) 
A total Sample size of 232 participants was calculated to make an inference. 
 
1.6.7 Inclusion Criteria 
The inclusion criteria for participants in the study were as follows: 
-Patients needed to be 18years and older 
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-Patients had to be diagnosed with any individual or combination of the 
following 4 diseases namely HIV, Type 2 Diabetes, Hypertension and 
Dyslipidaemia. 
-Patients had to be receiving treatment, from the private health care sector in the 
eThekwini Municipality region. 
- Patients had to be on prescribed medication treatment for a period of 6 months 
or more. 
-Patients were required to provide signed informed consent. 
 
1.6.8 Exclusion Criteria 
The following patients were excluded from the study: 
-Patients younger than 18 years  
-Patients not afflicted with any of the 4 diseases under investigation 
-Patients not on prescribed medication for a minimum period of 6months.  
 
1.6.9 Data analysis techniques 
The data collected from the questionnaire was coded into numerical input and captured 
electronically onto Microsoft excel ®. The coded data was then exported to SPSS ® statistical 
package 24 and analysed. The demographic details were analysed using frequency tables and 
cross tabulation descriptive statistics to generate summaries. Associations between variables 
were correlated using Pearson Chi and Spearman Rho Correlation coefficients to determine 
significance.  A p value of 0.05 or less and  𝜌 value of +0 or – 0 was considered statistically 
significant.  
 
1.6.10 Ethical considerations 
 This study had been ethically reviewed and approved by the University of KwaZulu-Natal 
Biomedical Research Ethics Committee, approval number BFC307/16 
 
1.7 Dissertation structure  
 
Chapter 1:   
 
- Introduction:  Background and literature review 
- Core research problem and Clinical significance of the study 
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- Purpose of the study 
- Formulation of aims and specific objectives of the study 
- Research Methodology 
- Ethical Considerations 
 
Chapter 2: 
 
- Presentation of manuscript titled, “Investigation of the medication 
adherence behaviour and the factors that influence such behaviour 
amongst private sector patients with certain communicable and/or non-
communicable diseases.” 
 
Chapter 3:  
 
- Presentation of manuscript titled, “Medication usage and adherence 
behaviour of patients with communicable and non-communicable 
disease in the private health care sector of eThekwini, KwaZulu-Natal.” 
 
Chapter 4: 
 
- Synthesis  
-Limitations of the study  
- Recommendations  
- Conclusion 
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ABSTRACT 
Background  
Medication adherence is a significant factor contributing towards the achievement of treatment 
goals.  This study was conducted to provide insight into the medication adherence behaviour of 
private sector patients afflicted with communicable and non-communicable chronic diseases. 
Objectives 
To investigate the medication adherence behaviour of patients suffering from Non-
Communicable diseases and Communicable diseases in the private health care sector of the 
eThekwini Municipality of KwaZulu-Natal.  
Methods  
A self-reported medication adherence questionnaire was used to obtain data, from 233 patients 
afflicted with Human Immunodeficiency Virus (HIV), Type 2 Diabetes Mellitus, Hypertension 
and Dyslipidaemia. The questionnaire focused on factors that influence medication adherence as 
well as the number of days of medication missed during the last 30 days. Data were collected 
and analysed using SPSS. 
Results  
Majority of participants were aged between 51-60 years (26.6%), and were of male gender 
(52.8%). An almost equal number of participants were afflicted with single disease (n=116) or 
multiple diseases (117). Hypertension was the most prevalent ailment (n=167), followed by 
Type 2 Diabetes (n=113), Dyslipidaemia (n=94) and HIV (n= 26). Over 62% of participants 
reported not missing any medication during the last 30 days. More than 21% had stated missing 
1-2 days of their medication and 15.9% reported missing 3 or more days of medication during 
the last 30 days. With regards to single diagnosis, the highest percentage of adherence was 
reported in participants afflicted with Hypertension (60.6%), and Type 2 diabetes (58.3%). HIV 
and Dyslipidaemia had the lowest rates of adherence as 45% (n=9) of HIV only afflicted 
participants and 57.1% (n=4) of Dyslipidaemia only afflicted participants reported missing 1 or 
more days of their medication. The highest rate of non-adherence was found in the age group of 
participants 51-60 years old, while the highest rate of adherence was found in the group aged 70 
years+. Reasons for non-adherence included cost, forgetting to take medication, running out of 
medication, stopping medication because it made them feel worse or gave a side effect and 
having difficulty with time schedules or having medication with/without food.   
Conclusion 
Participants afflicted with communicable and non-communicable diseases in the private health 
care sector have sub-optimal medication adherence. No significant correlations were found 
between having a particular disease and the rate of adherence, but participants afflicted with 
HIV only and Dyslipidaemia only where the least adherent. Reasons for non-adherence were  
similar to other studies. 
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INTRODUCTION 
 
South Africa is burdened with high rates of communicable and non-communicable diseases 
(NCD) [1- 3]. One method of tackling the growing burden of these diseases and preventing the 
complications that ensue is addressing the issue of medication adherence. Medication adherence 
has been defined as the extent to which patients take medications as prescribed by their health 
care providers [4, 5].  The rate of adherence is frequently described as a percentage of the 
prescribed doses of the medication taken over a specified period of time [6]. 
The complete benefit of prescribed medications can only be achieved if patients abide to their 
medication therapies [5]. However many patients experience difficulty in following prescribed 
regimens [7] due to various reasons. Common reasons for not adhering to prescribed medication 
include: forgetfulness, other priorities, decision to omit, lack of understanding, complexity of 
regimen, side effects, and costs [8-10]. 
International studies have produced immense data on the medication adherence behaviour of 
patients in both private and public health facilities. Whilst local studies have focused and given 
more insight into the medication adherence behaviour of public sector patients with chronic 
ailments.  
For example, in the Heart and Soul study, the risk of cardiovascular events associated with self-
reported medication non-adherence were prospectively evaluated in 1015 outpatients.  Eighty 
three patients (8.2%) where found to be non-adherent to their regimens and one hundred and 
forty six (14.4%) developed cardiovascular events. Non-adherence was defined as taking 
medications as prescribed 75% of the time or less. It was concluded that medication non 
adherence is associated with a 2 fold increase in acquiring cardiovascular events [11]. 
In another study conducted in Ontario in 2002 among elderly patients, 25% of patients 
prescribed a statin therapy for acute coronary syndrome or chronic coronary artery disease had 
discontinued their therapy at 6 months after initiation. Patients were evaluated on their 
medication adherence over two years and it was suggested that many patients initiating statin 
therapy may receive little or no benefit from statins because of early discontinuation [12].  
In Africa it was revealed that one in every five respondents did not adhere well to their diabetic 
medication (n=88). This study was conducted in Uganda between the years 2012-2013 at two 
general hospitals (n=521).The results were based on patient’s self-reports at an adherence index 
of 80%. Factors that contributed towards adherence included length of time on treatment, drug 
availability and receiving prior diabetic education [13]. 
South African studies conducted at public health facilities have revealed sub-optimal rates of 
medication adherence as well. Peltzer et al conducted a study in 2007 investigating the Anti-
Retroviral Treatment (ART) adherence behaviour of patients from 3 public hospitals in 
KwaZulu – Natal (KZN).  Five hundred and nineteen patients were interviewed on their 
adherence behaviour taking into consideration adherence to time, dose and food. The results 
revealed that 82.9% (n=427) of the participants where 95% adherent to their regimens using the 
30-day visual analogue scale. About 72.4% were adherent to the time advised to take their 
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medication and 71.7% were adherent to taking their medication as prescribed with regards to 
food [14]. 
A self-reported chronic medication adherence survey conducted by Mathevula in 2013 at the 
Waterberg District hospital interviewed 307 Patients afflicted with Human Immunodeficiency 
Virus (HIV), Diabetes, and Hypertension (HTN) regarding adherence to their medication 
regimens. Patients with more than one chronic disease had the lowest adherence rate in this 
group. The highest adherence was found in patients with HIV. Eighty one percent of the 
respondents said they never had missed to taking their treatment as prescribed in the previous 
month. Forty two (21%) of the respondents taking ARTs indicated that they missed a dose at 
least once in the previous month. Fifteen (31%) of those on anti-hypertensives said they missed 
a dose in the previous month. Ten (28%) of those taking anti-diabetics had missed a dose in the 
previous month. Among those on both anti-diabetics and anti-hypertensive’s, eight (34%) said 
they missed a dose in the previous month. Adherence was calculated as taking 95% and above 
of the prescribed medication for a month [15]. 
A literature search has revealed a paucity of studies in South Africa with regards to medication 
adherence in private sector patients afflicted with NCDs. To date no medication adherence 
studies investigating adherence rates in patients afflicted with NCDs were conducted in the 
private health care sector of South Africa. Only one study investigating the medication 
adherence of private sector HIV patients was identified. This study was conducted by Naidoo in 
2005 and investigated factors influencing Highly Active Anti-Retroviral Treatment (HAART) 
medication adherence in the private health care sector in eThekwini. This study revealed sub-
optimal medication adherence rates as forty nine out of fifty five (89.1%) private sector 
HAART patients were non-adherent to their medication regimes, where non-adherence was 
regarded as missing one day or more of their therapy [9].  
Due to the lack of data on medication adherence behaviours in the private health care sector of 
South Africa, this study was conducted to provide insight on this subject. This study aimed to 
investigate the medication adherence behaviour of patients suffering from communicable and 
NCDs in the private health care sector of the eThekwini Municipality of KZN. 
 
METHODOLOGY 
Study design 
A cross sectional, analytical and descriptive study was conducted. Quantitative data was 
collected using a closed ended self-reported medication adherence questionnaire.  
Study population 
The study population consisted of patients receiving health care treatment from private sector 
doctors practising in the eThekwini Municipality of KZN. The required sample size to make an 
inference was 232. 
Study period 
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The study was conducted over a period of two months from 18 October 2017 – 18 December 
2017.  
Sampling strategy 
Study participants were recruited into the study via stratified sampling. Access to study 
participants was granted via random and convenient sampling of doctors. A list of General 
Practitioners (GP) was obtained from the med page section of the yellow pages directory 
available in the eThekwini region. A letter was sent via email/fax to each of the doctors’ 
practices after telephonically contacting the rooms to inform them of the study. The letter 
requested permission from the GPs to allow the researcher to meet patients receiving care at the 
GPs practice. A total of 14 GPs consented to participate in the study, 5 doctors via random 
sampling and 9 doctors via convenient sampling.  A time and date to randomly interview 
patients at practices was agreed upon with the GP. Bias was avoided in the selection process as 
neither the GP nor researcher had any influence over who chose to receive care on that 
particular day. 
Inclusion Criteria 
Study participants needed to be 18years and older, diagnosed with any single or combination of 
the following 4 diseases namely HIV, Type 2 Diabetes (T2D), Hypertension (HTN) and 
Dyslipidaemia (DYS). Participants had to be receiving treatment from the private health sector 
in the eThekwini Municipality region and had to be on prescribed medication treatment for a 
period of 6 months or more. Patients not meeting these criteria were excluded. 
Data analysis techniques 
Data collected from the questionnaires were coded numerically, captured electronically onto 
Microsoft excel ®, exported to SPSS ® statistical package version 24 and analysed. 
Demographic details were analysed using frequency tables and cross tabulation descriptive 
statistics. Associations between variables were correlated using Pearson Chi and Spearman Rho 
Correlation coefficients to determine significance.  A p value of 0.05 or less and  𝜌 value of +0 
or – 0 was considered statistically significant. 
Ethical considerations 
Ethical approval was granted from the University of KwaZulu-Natal Biomedical Research 
Ethics Committee, approval number BFC307/16. 
Main Outcome measures. 
To extract information on participants’ demographic details, factors contributing to medication 
adherence and the number of missed days of medication during the last 30 days. For the 
purposes of this study medication adherence was categorised as follows: 
0 days missed - 100% adherent 
1-2 days missed - 96.6-93.3% adherent 
3 or more days - 90% adherent, and less 
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Since patients were afflicted with a combination of diseases and HIV requires an adherence rate 
of 95% or more to suppress virus replication and prevent resistance, an adherence rate of 0 days 
missed or 100% was deemed acceptable.  
 
     RESULTS 
 
 Table 1:Demographic data 
Age 
Category   N Percentage  
18-30 7 3.0 
31-40 33 14.2 
41-50 54 23.2 
51-60 62 26.6 
61-70 53 22.7 
71-80 23 9.9 
81-90 1 .4 
Gender 
Category   N Percentage  
Female 110 47.2 
Male 123 52.8 
Highest level of Education 
Category   N Percentage  
Tertiary 75 32.2 
Secondary 81 34.8 
Primary 68 29.2 
No formal Education 9 3.9 
 
Bulk of participants were distributed between age groups 51-60 years. Majority of participants 
were of male gender. Majority of participants had secondary or tertiary education qualifications.  
 
Table2: Types of Diseases 
 Multiple 
Conditions  
T2D only HTN only HIV only DYS only 
N = 233 116 24 66 20 7 
% 49.8% 10.3% 28.3% 8.6% 3% 
      
An almost equal amount of participants were diagnosed with single (n=117) and Multiple 
(n=116) ailments. Hypertension was the most common chronic ailment (n=167), followed by 
Type 2 Diabetes (n=113), Dyslipidaemia (n=94) and HIV (n= 26).  With regards to single 
disease, ranking followed the same order apart for a higher number of participants afflicted with 
HIV than Dyslipidaemia, as seen in table 2. 
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Factors affecting medication adherence 
Table 3: Factors that affect adherence negatively 
Question  N % 
Ever stopped taking 
medication when feeling 
better 
40 17.2 
Stopped medication because 
it made you feel worse / gave 
a side effect 
49 21.0 
Ever felt you do not need the 
medication  
45 19.3 
Ever felt that skipping a few 
doses will not make a 
difference 
67 28.8 
Ever not taken medication 
because it’s too expensive 
22 9.4 
Sometimes forget to take 
medication by mistake  
127 54.5 
Not taken medication because 
forgot to pick up a refill 
42 18 
Not taken medication because 
it ran out  
60 25.8 
Ever forgot to take 
medication with when 
travelling away from home 
36 15.5 
Ever not taken medication 
because did not want anyone 
to see 
14 6 
Struggle with taking 
medication as prescribed for 
example at a specific time / 
with or without meals 
46 19.7 
Ever leave out pills because 
they too many 
28 12 
Ever leave out pills because 
you feel they too strong 
32 13.7 
Ever not taken medication 
because did not know how to 
take correctly 
15 6.4 
 
With regards to factors that contribute negatively towards adherence, 20.1% of participants 
stopped their medication as it made them feel worse or gave them a side effect. 28.8% felt that 
skipping a few doses of their medication will not make a difference and more than half reported 
forgetting to take their medication. Greater than one fourth reported not taking their medication 
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as it ran out and more than one eighth of participants reported forgetting to take their medication 
with them when they travelled away from home. One fifth of participants found it difficult to 
take their medication at a specific time or with/without meals.  
 
Table 4: Factors that affect medication adherence positively 
Question  N % 
Think it’s important to take 
medication exactly as 
prescribed by Doctor  
216 92.7 
Family knows about 
medication you take  
225 96.6 
Family helps remember to 
take medication  
176 75.5 
Feel get enough support from 
family to manage disease 
209 89.7 
 
With regards to factors contributing positively towards adherence, majority (92.7%) agreed that 
it is important to take their medication exactly as prescribed by their doctor. Almost all 
participants stated that their family knew about the medication they take, however only 89.7% 
felt that they get enough support from their family to manage their conditions and only 75.5% 
stated that their family helped them remember to take their medication.  
 
Table 5: Factors affecting medication adherence in participants with single diseases vs 
multiple 
Question T2D only 
(n=24)  
HTN only 
(n=66) 
DYS only 
(n=7) 
HIV only 
(n=20) 
Single 
(n=117) 
Multiple 
(n=116) 
Stopped taking medication 
when felt better 
4 (16.6%) 
p=0.945 
14(21.2%) 
p=0.303 
3(42.9%) 
p=0.067 
6 (30%) 
p=0.111 
27(23.1%) 
p=0.016 
13(11.2%) 
p=0.016 
Stopped medication because 
made patient feel worse / 
gave side effect 
6(25%) 
p=0.614 
13(19.7%) 
p=0.754 
2(28.6%) 
p=0.619 
5(25%) 
p=0.649 
26(22.2%) 
p=0.654 
23(19.8%) 
p=0.654 
Ever felt that they did not 
need to take medication 
5(20.8%) 
p=0.842 
15(22.7%) 
p=0.407 
2 (28.6%) 
p=0.529 
5(25%) 
p=0.500 
27(23.1%) 
p=0.144 
18(15.5%) 
p=0.144 
Felt that skipping a few 
doses will not make a 
difference 
5(20.8%) 
p=0.365 
18(27.2%) 
p=0.753 
3(42.9%) 
p=0.403 
7(35%) 
p=0.519 
33(28.2%) 
p=0.852 
34(29.3%) 
p=0.852 
Ever not taken medication 
because it’s too expensive 
0 (0%) 
p=0.095 
4(6.1%) 
p=0.267 
1(14.3%) 
p=0.656 
6(30%) 
p=0.001 
11(9.4%) 
p=0.983 
11(9.5%) 
p=0.983 
Do not think it is important 
to take medication exactly as 
prescribed by doctor  
2(8.3%) 
 p=0.837 
6(9.1%) 
p=0.508 
1(14.3%) 
p=0.470 
0(0%) 
p=0.189 
9(7.7%) 
p=0.815 
8(6.9%) 
p=0.815 
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Sometimes forget to take 
medication by mistake 
15(62.5%) 
p=0.406 
37(56.1%) 
p=0.765 
5(71.4%) 
p=0.361 
10(50%) 
p=0.672 
67(57.3%) 
p=0.396 
60 (51.7%) 
p=0.396 
Not taken medication 
because forgot to pick up a 
refill 
3(12.5%) 
p=0.457 
8(12.1%) 
p=0.140 
2(28.6%) 
p=0.461 
6(301111
510 
p=0.145 
19(16.2%) 
p=0.476 
23(19.8%) 
p=0.476 
Not taken medication 
because it ran out  
4(16.6%) 
p=0.283 
12(18.2%) 
p=0.097 
3(42.9%) 
p=0.293 
8(40%) 
p=0.127 
27(23.1%) 
 p=0.348 
33(28.4%) 
p=0.348 
Ever forgot to take 
medication with when 
travelling away from home 
1(4.2%) 
p=0.106 
10(15.2%) 
p=0.937 
1(14.3%) 
p=0.931 
6(30%) 
p=0.060 
18(15.3%) 
 p=0.978 
18(15.5%) 
p=0.978 
Ever not taken medication 
because did not want anyone 
to see 
0(0%) 
p=0.191 
1(1.5%) 
p=0.070 
0(0%) 
p=0.497 
7(35%) 
p=0.000 
8 (6.8%) 
p=0.593 
6(5.2%) 
p=0.593 
Family does not know about 
medication participant is 
taking  
0(0%) 
p=0.329 
3(4.5%) 
p=0.558 
0(0%) 
p=0.612 
2(10%) 
p=0.092 
5(4.2%) 
p=0.479 
3(25.9%) 
p=0.479 
Family does not help patient 
remember to take medication 
6(25%) 
p=0.949 
12(18.2%) 
p=0.161 
3(42.9%) 
p=0.250 
5(25%) 
p=0.953 
26(22.2%) 
p=0.424 
31(26.7%) 
p=0.424 
Feel they do not get enough 
support from their family to 
manage disease 
1(4.2%) 
p=0.297 
9(13.6%) 
p=0.292 
0(0%) 
p=0.363 
4(20%) 
p=0.136 
14 (11.9%) 
p=0.401 
10(8.6%) 
p=0.401 
Struggle with taking 
medication as prescribed for 
example at a specific time / 
with or without meals 
5(20.8%) 
p=0.887 
8(12.1%) 
p=0.066 
2(28.6%) 
p=0.551 
8(40%) 
p=0.017 
23(19.7%) 
 p=0.974 
23(19.8%) 
p=0.974 
Ever leave out pills because 
they feel there are too many  
0(0%) 
p=0.056 
4(6.1%) 
p=0.079 
0(0%) 
p=0.321 
3(15%) 
p=0.668 
7(5.9%) 
p=0.004 
21(18.1%) 
p=0.004 
Ever leave out pills because 
they feel the medication is  
too strong  
3(12.5%) 
p=0.853 
6(9.1%) 
p=0.196 
1(14.3%) 
p=0.966 
3(15%) 
p=0.836 
13(11.1%) 
p=0.243 
19(16.4%) 
p=0.243 
Ever not taken medication 
because did not know how to 
take correctly 
0(0%) 
p=0.175 
3(4.5%) 
p=0.459 
0(0%) 
p=0.481 
4(20%) 
p=0.014 
7(5.9%) 
 p=0.776 
8(6.9%) 
p=0.776 
 
A significant difference was found among participants with single vs multiple diseases. More 
participants with single diseases (n = 27) reported not taking their medication once they felt 
better. And more participants with multiple diseases (n=21) reported leaving out pills because 
they felt there were too many.   
Statistical significance was also found in participants afflicted with HIV alone (n=20) who 
reported not taking their medication because it’s too expensive (30%), not taking their 
medication because they did not want anyone to see (35%), struggling to take their medication 
at specific times / with or without food (40%) and not taking their medication because they did 
not know how to take them correctly (20%).  
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Zero participants afflicted with Type 2 diabetes reported leaving out pills because they felt there 
were too many (p=0.056).  
 
Medication adherence: Number of missed days of medication during the last 30 days  
Graph 1: Number of days missed of medication 
 
 
 
With regards to number of missed days of medication, a large percentage (n=146) had reported 
no days of missed medication.  50 participants stated they had missed 1-2 days of their 
medication and 37 reported having missed 3 or more days of medication during the last 30days. 
 
Table 6: Number of missed days of Medication: Single vs Multiple Diseases 
 T2d only 
 
HTN only DYS 
Only 
HIV only Single 
condition 
Multiple 
conditions 
how many days 
of medication 
not taken 
during last 
30days 
0 days 14(58.3%) 40(60.6%) 3(42.9%) 11(55%) 68(58.1%) 78(67.2%) 
1-2 days 8(33.3%) 13(19.7%) 2(28.6%) 3(15%) 26(22.2%) 24(20.7%) 
3 or more 
days 
2(8.3%) 13(19.7%) 
 
2(28.6%) 6(30%) 23(19.7%) 14(12.1%) 
Total 24 66 7 20 117 116 
p value  0.247 0.594 0.508 0.185 0.229 
 
0 days 
63%
1-2days 
21%
3 or more days 
16%
0 days
1-2days
3 or more days
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Participants afflicted with multiple diseases had higher adherence rates than participants with 
single diseases. In all categories of days missed, patients with multiple diseases reported less 
missed days than patients with single diseases as seen in Table 6.   
With regards to participants afflicted with single diseases, the highest percentage of adherence, 
with 0 days of missed medication, was reported in participants with Hypertension (60.61%), 
followed by Type 2 diabetes (58.33%), HIV (55%) and Dyslipidaemia (42.86%).  Participants 
afflicted with dyslipidaemia alone and HIV alone had the highest rate of non-adherence as 
28.6% of participants with dyslipidaemia alone and 30% of participants with HIV alone had 
reported missing 3 or more days of their prescribed medication.  
 
Table 7: Number of days of medication missed according to Age 
Age  18-40years 
(n=40) 
41-50years 
(n=54) 
51-60 
years 
(n=62) 
61-70 
years 
(n=53) 
70+ 
Years 
(n=24) 
How many 
days of 
medication did 
you not take 
during the last 
30days  
0days  22(9.44%) 32(13.73%) 33(14.16%) 39(16.74%) 20(8.58%) 
1-2 
days  
9(3.86%) 10(4.29%) 20(8.58%) 8(3.43%) 3(1.29%) 
3 or 
more 
days  
9(3.86%) 12(5.15%) 9(3.86%) 6(2.58%) 1(0.43%) 
p value  0.063 
𝜌 value -0.181 
 
The relationship between age and number of days of missed medication was found to be 
significant having a spearman’s rho correlation of -0.181 .The highest rate of overall non-
adherence was found in the group of participants aged 51-60 years old. Participants aged 41-
50years old had a higher rate of missing 3 or more days of their medication. While the highest 
rate of adherence was found in the group aged 70+ years. 
 
DISCUSSION 
This study found that adherence rates were sub-optimal for participants with communicable and 
non-communicable diseases as only 63% had missed zero days of their medication during the 
last 30 days. Although no significant difference amid adherence rates were found amongst 
participants with a particular disease, participants with Hypertension alone and Type 2 Diabetes 
alone were the most adherent and while participants with dyslipidaemia alone and HIV alone 
were the least adherent. 
The adherence rates found in this study concur with international studies that have found that 
20-50% of patients do not adhere to their prescribed medications [16] but is variable when 
compared to local studies.  For example a private sector HAART study [9] found that only 10.9% 
of participants were one hundred percent adherent to their HAART medication. While public 
sector self-reported adherence studies have found higher rates of medication adherence as more 
  20   
 
than 80% of participants had taken more than 95% of their medication during the previous thirty 
days [14, 15].  
Significant factors affecting medication adherence in this study with participants afflicted with 
HIV alone were not taking medication because it’s too expensive, not taking medication 
because they did not want anyone to see, struggling to take medication at specific times / with 
or without food and not taking medication because they did not know how to take them 
correctly. These findings correlate with that stated by Emamzadeh-Fard et al [18], where factors 
that reduce the rate of adherence in Sub-Saharan Africa were identified as cost, not informing 
patient's spouse and family about his/her disease, fear of stigma and complications following 
medication regimens. Naik et al had also found cost and poor medication knowledge to be 
factors contributing to poor adherence in their study as 75% of patients reported the cost of 
HAART to be an obstacle to adherence. Patients who understood their medication and how to 
use them were more adherent to their therapies than patients who did not [17].   
In this study, participants afflicted with multiple diseases were more adherent to their therapies 
than participants with single diseases. Participants with single diseases were more likely to stop 
their therapy when they felt better compared to participants with multiple diseases.  Jin [19] et al 
and DiMatteo [20] et al have proposed that greater disease severity is attributed to better 
compliance. This may be accurate in the sense that patients may perceive themselves as being at 
higher risk having more chronic illness diagnoses than a single diagnosis thus leading to better 
medication compliance. 
The relationship between age group and number of days of missed medication was found to be 
significant having a spearman’s rho correlation of -0.181.The highest rate of adherence was 
found in the group of participants aged 70 years old and above. This is consistent with 
systematic reviews conducted by Jin et al and Erickson et al who proposed that increasing age 
was a significant predictor of an increased likelihood of being adherent to medication therapies 
such as statins, antihypertensives, and antidiabetics [20, 21] . 
Common reasons recognised for poor adherence in this cohort, similar to other studies [8-10, 19], 
were forgetting to take medication, running out of medication, stopping medication because it 
made them feel worse or gave a side effect and having difficulty sticking to time schedules or 
having medication as prescribed with/without food. The effect of these factors on medication 
adherence can be reduced by individualising patient regimens to suit patients’ lifestyle and 
minimising known side effects of drugs. Technology such as short message service’s or apps on 
cell phones can be used as reminders to take medication daily or pick up medication refills.  
Dosage simplification has been found to be effective in increasing medication adherence rates 
[16] where practitioners prescribe regimens that require the lowest dosing frequency and are the 
least complex to administer.   
Although majority of participants felt that it is important to take their medication exactly as 
prescribed by their doctor, more than one fourth of participants felt that skipping a few doses of 
their medication would not make a difference to their health. Jin et al [19] have found that a 
patient’s understanding of their disease and treatment may not always be optimal. Some patients 
may not understand the effect medication therapies play in their treatment while some lack 
knowledge about the disease and the consequences of poor compliance. Others may be under 
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the impression that the need for medication was intermittent and stop their treatment 
presumptively. 
Family support has been shown to positively affect adherence. Although almost all participants 
in this study stated that their family knew about the medication they take, only 75% stated that 
their family helps them remember to take their medication. Greater effort may need to be placed 
on involving family members in therapy regimens as the risk of non-adherence has been stated 
to be 1.35 times higher in patients who do not receive emotional support [22]. Social support has 
been identified as a stress buffer, may help change emotional states, increase self-efficacy, and 
influence change in adverse health behaviours [23]. 
 
LIMITATIONS 
The rate of adherence was measured categorically as the number of days missed in a 30 day 
cycle and not individually. In this study the sample population consisted of a minority of 
patients afflicted with dyslipidaemia and HIV.  
 
RECOMMENDATIONS 
Further research needs to be conducted to determine if age is a significant predictor of 
adherence. The stigma of taking HIV medication seems to still be a prevalent issue affecting 
patients with HIV/AIDS. This along with the cost of therapy and understanding how their 
medication works and how to take them correctly need to be addressed when deciding to treat.  
  
CONCLUSIONS 
This study found that participants afflicted with communicable and non-communicable diseases 
in the private health care sector have sub-optimal medication adherence. Although no 
significant correlations were found between having a particular disease and adherence, 
participants afflicted with HIV and Dyslipidaemia alone were the least adherent to their 
medication. Patients with HIV still struggle with cost of their medication, taking their 
medication at particular times and have to take their medication covertly so people do not see. 
In this study age was proposed to be a predictor of adherence however its effects should be 
investigated further.  
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A second manuscript focusing on medication adherence rates in patients with single and 
multiple diseases as well as the types of medication they use has been prepared for publication. 
This paper is titled “Medication usage and adherence behaviour of patients with communicable 
and non-communicable diseases in the private health care sector of eThekwini, KwaZulu-Natal. 
It is believed that the second manuscript will be able to shed even more light on the topic of 
medication adherence behaviours of patients in the private health sector of South Africa. 
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ABSTRACT 
Background 
Information regarding the medication usage behaviour of private sector patients afflicted with 
HIV, Type 2 Diabetes, Hypertension and Dyslipidaemia remain sparse in South Africa. A small 
amount of dated information does exist about the types of medication commonly prescribed to 
patients with non-communicable chronic diseases but further research is needed. Although it is 
assumed that patients would be prescribed similar medications according to treatment 
guidelines, this needs to be confirmed. 
Objectives 
To determine the type of medication prescribed to patients afflicted with communicable and 
non-communicable diseases in the private health care sector of eThekwini as well as to 
determine the adherence behaviour of patients with single and multiple diseases. 
Methods 
Data on medication usage, factors influencing adherence and the number of days of medication 
missed were extracted from 233 private sector patients using a self-reported medication 
adherence questionnaire. Data was collected and analysed using SPSS. 
Results 
Majority of participants were male and aged between 51-60 years (26.6%). An almost equal 
number of participants were afflicted with single disease (n=116) or multiple diseases (117). 
Hypertension was the most prevalent ailment (n=167), followed by Type 2 Diabetes (n=113), 
Dyslipidaemia (n=94) and HIV (n= 26). Biguanides (89.38%) and Sulphonylureas (46.02%) 
were the most common prescribed classes of medication used in Type 2 diabetics. The most 
commonly prescribed class of drugs for hypertension were the diuretics (42.73%), fixed dose 
combination drugs (29.34%), ACE inhibitors (28.74%) and Calcium channel blockers (25.75%). 
All participants afflicted with dyslipidaemia were prescribed a statin therapy (100%) and more 
than half (56.38%) were prescribed low dose aspirin. With regards to HIV, 92.3% of 
participants were on combination drug therapy. More participants with single diseases (23.1%) 
stopped taking their medication when they felt better compared to participants with multiple 
diseases (11.2%). While more participants with multiple diseases (18.1%) left out pills because 
they felt there were too many when compared to single diseases (5.9%). 
Conclusion  
Patients in the private sector are prescribed similar classes of drugs for their conditions in line 
with treatment guidelines. Patients with multiple diseases are more likely to leave out pills 
because they feel there are too many, while patients with single diseases are more likely to stop 
taking their medication when they feel better. 
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INTRODUCTION 
 
Information regarding the medication usage and adherence behaviour of patients afflicted with 
chronic diseases in the private health care sector of South Africa remain unclear. To date, only 
one study investigated the types of medication commonly prescribed to patients with chronic 
ailments in both the public and private health care sectors in South Africa [1] and none focusing 
on private health care sector patients only. 
In 1998, Steyn et al conducted a national chronic medication usage study in South Africa. This 
study investigated the chronic medication usage of both public and private health care sector 
patients with Non-communicable diseases (NCDs). The findings revealed that patients were not 
prescribed medications according to recommended national treatment guidelines but were 
prescribed more expensive and irrational drugs. The most common class of drugs prescribed for 
diabetes were ranked sulphonylureas, biguanides and insulins. While for hypertensives the most 
common classes of drugs prescribed were ranked diuretics, renin-angiotensin inhibitors and 
calcium channel blockers. The authors suggested that the use of an essential drug list (EDL) 
could result in a more rational and cost-effective pattern of chronic drug use in the country [1]. 
The current assumption is that prescribing patterns have transformed over the last 8 years and 
that patients, more specifically in the private health care sector, would be prescribed 
medications according to recommended treatment guidelines set by professional societies. 
Chronic medication adherence studies have revealed sub-optimal rates of medication 
compliance, with patients missing pills, sometimes intentionally, for various reasons. Non-
adherence rates have been found to be higher in patients’ who are often prescribed new therapy 
as compared to those with existing medication regimens [2]. This may suggest that patients with 
single diagnosis have lower adherence rates than those with co-morbid diseases. However a 
study conducted at a public health facility in South Africa found that patients with co-morbid 
conditions such as diabetes, hypertension and HIV had lower adherence rates than those with 
single diagnosis.  
Human Immunodeficiency Virus (HIV), Hypertension (HTN), Type 2 Diabetes (T2D) and 
Dyslipidaemia (DYS) are the most prevalent chronic diseases afflicting medical scheme patients 
in South Africa according to the Council of Medical Schemes (CMS), however there have not 
been many studies aimed at extracting information on these conditions [3].  This study aimed to 
investigate the medication usage behaviour of patients afflicted with communicable and non-
communicable diseases in the private health care sector of eThekwini, KwaZulu-Natal (KZN). 
This paper focuses on the types of medication prescribed to patients afflicted with any of the 
four disease i.e. HIV, Type 2 Diabetes Mellitus, Hypertension and Dyslipidaemia as well as to 
determine if rates of adherence differ amongst patients afflicted with single and multiple 
diseases.  
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METHODOLOGY 
 
Study design 
A cross sectional, analytical and descriptive study was conducted. Quantitative data was 
collected using a closed ended self-reported medication adherence questionnaire.  
Study population 
The study population consisted of patients receiving health care treatment from private sector 
doctors practising in the eThekwini Municipality of KwaZulu-Natal. The required sample size 
to make an inference was 232. 
Study period 
The study was conducted over a period of two months from 18 October 2017 – 18 December 
2017. Patients were interviewed while receiving care from General Practitioners in the 
eThekwini Municipality. 
Sampling strategy 
Study participants were recruited into the study via stratified sampling. Access to study 
participants was granted via  random and convenient sampling of doctors. A list of General 
Practitioners (GP) was obtained from the med page section of the yellow pages directory 
available in the eThekwini region. A letter was sent via email/fax to each of the doctors’ 
practices after telephonically contacting the rooms to inform them of the study. The letter 
requested permission from the GPs to allow the researcher to meet patients receiving care at 
their GPs practice. A total of 14 GPs consented to participate in the study (5 doctors via random 
sampling and 9 doctors via convenient sampling). A time and date to randomly interview 
patients at practices was agreed upon with the GP. Bias was avoided in the selection process as 
neither the GP nor researcher had any influence over who chose to receive care on that 
particular day. 
Inclusion Criteria 
Study participants needed to be 18 years and older, diagnosed with any single or combination of 
the following 4 diseases namely HIV, Type 2 Diabetes, Hypertension and Dyslipidaemia. 
Participants had to be receiving treatment, from the private health care sector in the eThekwini 
Municipality region and had to be on prescribed medication treatment for a period of 6 months 
or more. Participants were required to provide informed consent. Patients not meeting these 
criteria were excluded. 
Data analysis techniques 
Data collected from the questionnaires were coded numerically and captured electronically onto 
Microsoft excel ®. The coded data was then exported to SPSS ® statistical package version 24 
and analysed. The demographic details were analysed using frequency tables and cross 
tabulation descriptive statistics. Associations between variables were correlated using Pearson 
Chi coefficients to determine significance.  A p value of 0.05 or less was considered statistically 
significant. 
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Ethical considerations 
Ethical approval was granted from the University of KwaZulu-Natal Biomedical Research 
Ethics Committee, approval number BFC307/16. 
Main Outcome measures 
To extract information on participants’ demographic details, medication usage, factors 
contributing to medication adherence and the number of missed days of medication during the 
last 30 days. For the purposes of this study medication adherence was categorised as follows: 
0 days missed - 100% adherent 
1-2 days missed - 96.6-93.3% adherent 
3 or more days - 90% adherent and less 
 
Since patients were afflicted with a combination of diseases and HIV requires an adherence rate 
of 95% or more to suppress virus replication and prevent resistance, an adherence rate of 0 days 
missed or 100% was deemed acceptable.  
 
 
RESULTS 
 
Demographics 
 Table 1:Demographic data 
 
Age 
Category   N Percentage  
18-30 7 3.0 
31-40 33 14.2 
41-50 54 23.2 
51-60 62 26.6 
61-70 53 22.7 
71-80 23 9.9 
81-90 1 .4 
Gender 
Category   N Percentage  
Female 110 47.2 
Male 123 52.8 
Highest level of Education 
Category   N Percentage  
Tertiary 75 32.2 
Secondary 81 34.8 
Primary 68 29.2 
No formal Education 9 3.9 
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Table 2: Types of Diseases 
 
 Multiple 
Conditions  
Type 2 
diabetes  
Only 
Hypertension 
Only 
HIV only 
Dyslipidaemia 
only 
N = 233 116 24 66 20 7 
% 49.8% 10.3% 28.3% 8.6% 3% 
      
 
An almost equal amount of participants were diagnosed with single (n=117) and Multiple 
(n=116) ailments. Hypertension was the most common chronic ailment (n=167), followed by 
Type 2 Diabetes (n=113), Dyslipidaemia (n=94) and HIV (n= 26).  With regards to single 
disease, ranking followed the same order apart for a higher number of participants afflicted with 
HIV than Dyslipidaemia, as seen in table 2.  
 
 
Self-Medication usage 
Graph 1: Self-medication usage of Participants 
 
 
 
A very small percentage of the cohort were using self-medication. The types of self-medication 
used are indicated in graph 1.  
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Prescribed Medication usage 
 
Type 2 Diabetes 
 
Graph 2: Medication Prescribed for Type 2 Diabetes 
 
 
 
 
A total of 113 participants were afflicted with Type 2 Diabetes. Patients were prescribed one or 
more of the following classes of drug as seen in graph 2. The most common class of drug 
prescribed was Biguanides, in which the drug Metformin (n=101) falls categorically. This was 
followed by the group Sulfonylureas (n=52), insulins (n=26), Combination Therapies (n=3), 
Dipeptidyl peptidase (DPP) - 4 inhibitors (n=1) and Glucagon-like peptide (GLP)-1 agonists 
(n=1). No patients where prescribed Meglitinides, Alpha Glucosidase inhibitors or 
Thiazolidiones.  
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Hypertension 
 
Graph 3: Medication prescribed for Hypertension 
 
 
 
 
A total of 167 participants were afflicted with Hypertension. Patients where prescribed one or 
more of the following medication classes as seen in graph 3. Diuretics (42.7%), fixed dose 
combination therapy (29.3%), ACE inhibitors (28.7%) and Calcium channel blockers (25.7%) 
were the most popular therapies prescribed for hypertension as seen in graph 3. 
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Dyslipidaemia 
 
Graph 4: Medication Prescribed for Dyslipidaemia 
 
 
 
 
A total of 94 participants were afflicted with dyslipidaemia and were all prescribed a statin. 
Fifty three participants were prescribed aspirin to prevent blood clots and only 1 participant was 
prescribed a fibrate. No participants were prescribed drugs from the niacin or bile acid resin 
class of medication.  
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HIV 
Graph 5: Medication prescribed for HIV 
 
 
Majority of the participants afflicted with HIV were prescribed one or more of the following 
classes of drugs: a fixed dose regimen (92.3%), a Non-nucleoside reverse transcriptase inhibitor 
(NNRTI) regimen (11.5%) and a Nucleoside reverse transcriptase inhibitor (NRTI) regimen 
(7.7%) and 15.4% of participants were on Co-Trimoxazole therapy. No participants were 
prescribed a Protease inhibitor (PI).  
 
Factors affecting medication adherence 
 
Table 3: Factors affecting medication adherence in participants with single diseases vs 
multiple 
Question 
Single 
(n=117) 
Multiple 
(n=116) 
p value  
Stopped taking medication when participant felt better 
27(23.1%) 
 
13(11.2%) 
 
0.0016 
Stopped medication because made patient feel worse / gave 
side effect 
26(22.2%) 
 
23(19.8%) 
 
0.654 
Participant ever felt that they did not need to take medication 
27(23.1%) 
 
18(15.5%) 
 
0.144 
Felt that skipping a few doses will not make a difference 
33(28.2%) 
 
34(29.3%) 
 
0.852 
Ever not taken medication because it’s too expensive 11(9.4%) 11(9.5%) 0.983 
2
4
3
2
0
4
C O M B I N A T I O N  
D R U G  
N N R T I N R T I P I C O - T R I M O X Z O L E
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Do not think it is important to take medication exactly as 
prescribed by doctor 
9(7.7%) 
 
8(6.9%) 
 
0.815 
Sometimes forget to take medication by mistake 
67(57.3%) 
 
60 (51.7%) 
 
0.396 
Not taken medication because forgot to pick up a refill 
19(16.2%) 
 
23(19.8%) 
 
0.476 
Not taken medication because it ran out 
27(23.1%) 
 
33(28.4%) 
 
0.348 
Ever forgot to take medication with when travelling away from 
home 
18(15.3%) 
 
18(15.5%) 
 
0.978 
Ever not taken medication because did not want anyone to see 
8 (6.8%) 
 
6(5.2%) 
 
0.593 
Family does not know about medication participant is taking 
5(4.2%) 
 
3(25.9%) 
 
0.479 
Family does not help patient remember to take medication 
26(22.2%) 
 
31(26.7%) 
 
0.424 
Feel they do not get enough support from their family to 
manage disease 
14 (11.9%) 
 
10(8.6%) 
 
0.401 
Struggle with taking medication as prescribed for example at a 
specific time / with or without meals 
23(19.7%) 
 
23(19.8%) 
 
0.974 
Ever leave out pills because they feel there are too many 
7(5.9%) 
 
21(18.1%) 
 
0.004 
Ever leave out pills because they feel the medication is  too 
strong 
13(11.1%) 
 
19(16.4%) 
 
0.243 
Ever not taken medication because did not know how to take 
correctly 
7(5.9%) 
 
8(6.9%) 
 
0.776 
 
A significant difference was found among participants with single vs multiple diseases. A 
higher number of participants with single diseases (n = 27) reported not taking their medication 
once they felt better while more participants with multiple diseases (n=21) reported leaving out 
pills because they felt there were too many.   
 
Storage of medication in household 
 
Table 4: Storage of medication  
Place in home  N % 
Kitchen  91 39.1 
Bathroom  5 2.1 
Bedroom  112 48.1 
Handbag  12 5.2 
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Refrigerator  20 8.6 
Lounge 8 3.4 
Dining room  6 2.6 
Work draw  1 0.4 
 
The three most frequent areas of the home for the storage of medication were the bedroom, 
kitchen and refrigerator as seen in table 6.  
 
Medication adherence according to number of missed days of medication during the last 
30 days 
 
Table 5: Number of missed days of medication: Single vs Multiple Diseases 
 Single condition Multiple conditions 
how many days of medication not 
taken during last 30days 
0 days 68(58.1%) 78(67.2%) 
1-2 days 26(22.2%) 24(20.7%) 
3 or more days 23(19.7%) 14(12.1%) 
Total 117 116 
p value  0.229 
 
Participants afflicted with multiple diseases had higher adherence rates than participants with 
single diseases. In all categories of days of medication missed, patients with multiple diseases 
reported less missed days of medication than patients with single diseases as seen in table 7.   
 
 
DISCUSSION 
To date very little data exists with regards to patients’ medication usage behaviour in the private 
health care sector of South Africa. In this cohort, the most prevalent diseases were ranked as 
follows: Hypertension, Type 2 Diabetes, Dyslipidaemia and HIV. This is similar to the pattern 
reported by the Council for Medical Schemes in their 2015 report where Hypertension took the 
number one ranking for most prevalent disease and HIV the fourth with regards to diseases 
afflicting medical scheme beneficiaries in South Africa. Although more participants were 
afflicted with Type 2 Diabetes than Dyslipidaemia in this cohort, the opposite was true for 
majority of medical scheme beneficiaries in South Africa [3].   
Medication usage Behaviour 
Self-medication usage was evident in this study, though less than 10% of participants admitted 
to using this type of therapy to manage their diseases. This varies with higher rates of 
complementary and alternative medication (CAM) usage found in a study conducted in KZN, 
South Africa [4] and a study conducted in the United States [5]. It is evident that patients are 
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becoming more responsible and independent with regards to their health, especially in the sense 
of the CAM they use over the counter to help regulate their diseases. Self-medication when 
practised correctly, can lead to savings for patients and the healthcare system as stated by 
Menton and Van Schoor [6].  Questions do exist as to whether healthcare practitioners are aware 
of the self-medications patients use simultaneously with prescribed regimens and if their use 
impacts therapeutic outcomes. 
With regards to medications prescribed to treat communicable and non-communicable diseases 
in this study, similar patterns of prescribing corresponding to recommended treatment 
guidelines was evident. This is contrary to that found in by Steyn et al [1], were prescribing 
patterns were erratic and not following patterns recommended by treatment guidelines.  
With regards to diabetes, Biguanides and Sulphonylureas were the most common prescribed 
medication classes in this study. When compared to 1998, Sulphonylureas were more 
commonly prescribed than biguanides during that era. Metformin is the recommended drug of 
choice for monotherapy, while sulphonylureas are the drug of choice in patients who are 
intolerant to the side effects of metformin. This is endorsed by the Society of Endocrinology, 
Metabolism and Diabetes of South Africa in 2012 [7].  
Participants afflicted with hypertension were frequently prescribed a diuretic, combination drug, 
Angiotensin Converting Enzyme (ACE) inhibitor or Calcium channel blocker in this study. This 
is consistent with practice guidelines outlined by the Southern African Hypertension Society in 
2014 [8], were first-line drug therapy for uncomplicated hypertension consists of low-dose 
diuretics, calcium channel blockers or an ACE inhibitor /Angiotensin Receptor Blocker (ARB). 
Combination therapy has been recommended as the drug of first choice in patients were the 
blood pressure measurement is more than 20/10 mmHg above goal. It is notable to mention the 
increasing use of combination therapy in this disease group as compared to usage during 1998 
[1]. 
For dyslipidaemia, the drug of choice in this study was a statin regimen. The second most 
commonly prescribed drug in this group was aspirin therapy. These findings correlate with the 
dyslipidaemia treatment guidelines set by the South African Heart Association (SA Heart) and 
the Lipid and Atherosclerosis Society of Southern Africa (LASSA) [9]. Low dose aspirin has 
been shown to reduce rates of cardiovascular events [10] which may explain the frequent use in 
these patients.    
Fixed-dose combinations (FDCs) were the most prevalent medicines used in patients afflicted 
with HIV in this study. This is in accordance with treatment guidelines issued by the Southern 
African HIV clinicians’ society in 2015 [11]. HIV is a chronic ailment that requires high 
adherence rates to suppress viral replication and prevent treatment failure [12]. Fixed dose 
combination drugs have been recognised to increase adherence rates among patients with 
chronic ailments [13].  
Rates of adherence single vs multiple disease 
An interesting finding in this study was that medication adherence differed among participants 
according to the number of diseases they were afflicted with. Participants afflicted with multiple 
diseases in this study were more adherent to their therapies than participants with single 
diseases. Participants with single diseases were more likely to stop their therapy when they felt 
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better as compared to participants with multiple diseases. This finding is in contrast to a study 
conducted by Mathevula in 2013 [14] but ties in with the findings of Jin [15] and Di Matteo [16].  In 
Mathevulas study, public sector patients afflicted with similar chronic conditions, were found to 
be more adherent if they were afflicted with a single condition rather than multiple conditions, a 
direct contrast to this study. Jin [15] et al and DiMatteo [16] et al have proposed that patients with 
greater disease severity have better compliance to their treatment regimens. Reasons for this 
maybe that patients perceived themselves as being at a higher risk, having more chronic 
illnesses and may thus may have better compliance than those with single diseases.  
Another interesting finding was that patients with multiple diseases were more likely to leave 
out pills as they felt there were too many. This issue should be taken into consideration when 
prescribing regimens for patients with co-morbid ailments. The use of combination therapy 
should be preferred in such patients to reduce pill burden.  
Medication Storage 
Popular storage areas for medication as evident in this study remain the bedroom and kitchen. 
This is similar to results found in numerous Middle Eastern studies [17-19] on home medication 
storage, where the bedroom, refrigerator and kitchen were the most frequently used areas to 
store medication at home. Keeping medication in areas of the home which are frequently used 
will help schedule medication taking into daily activities which promote adherence. Due to the 
absence of medication storage studies in South Africa, future studies should be conducted to 
elucidate more information on this topic, as storage areas can accelerate medication degradation 
and affect medication performance [17].  
 
LIMITATIONS 
The rate of adherence was measured categorically as the number of days of medication missed 
in a 30 day cycle and not individually.  
 
RECOMMENDATIONS 
Future studies investigating chronic medication adherence should focus on information 
regarding which drugs patients leave out intentionally and why. The effect of self-medication 
usage on therapeutic outcomes and health practitioners’ knowledge of such should be 
investigated. 
 
CONCLUSIONS 
This study found that patients in the private health care sector are prescribed medication that 
align with treatment guidelines. Patients with single diseases are more likely to stop treatment 
once they feel better while those with multiple diseases are more likely to leave out pills as there 
are too many. 
 
  39   
 
REFERENCES 
1. Steyn K, Bradshaw D, Norman R, Bradley H, Laubscher R. The use of prescribed drugs 
for common chronic conditions in South Africa in 1998. Pharmacoepidemiology and 
drug safety. 2005 Feb 1;14(2):91-100. 
2. Barber N, Parsons J, Clifford S, Darracott R, Horne R. Patients’ problems with new 
medication for chronic conditions. Quality and Safety in health care. 2004 Jun 
1;13(3):172-5. 
3. Council for Medical Schemes. Prevalence of chronic diseases in the population covered 
by medical schemes in South Africa. 2015. Available from: 
http://www.medicalschemes.com/files/Research%20Briefs/RBPrevCD20150128.pdf. 
[Accessed 21 March 2017] 
4. Peltzer K, Friend-du Preez N, Ramlagan S, Fomundam H. Use of traditional 
complementary and alternative medicine for HIV patients in KwaZulu-Natal, South 
Africa. BMC Public Health. 2008 Jul 24;8(1):255 
5. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative 
medicine use among adults: United States, 2002. InSeminars in integrative medicine 
2004; 2, (2):54-71. 
6. Menton T, van Schoor J. Principles of self-medication. South African Pharmacist's 
Assistant. 2007;5(1):5-6 
7. Amod A, Ascott-Evans BH, Berg GI, Blom DJ, Brown SL, Carrihill MM. The 2012 
SEMDSA guidelines for the management of type 2 diabetes. J Endocrinol Metab 
Diabetes S Afr. 2012; 17(2):S4. 
8. Seedat YK, Rayner BL. South African hypertension guideline 2011: guideline. South 
African Medical Journal. 2012; 102(1):60-83. 
9. Klug EQ, Raal FJ, Marais AD, Taskinen MR, Dalby AJ, Schamroth C, Rapeport N, 
Jankelow D, Blom DJ, Catsicas R, Webb DA. South African dyslipidaemia guideline 
consensus statement: A joint statement from the South African Heart Association (SA 
Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). South 
African Family Practice. 2015; 57(2):22-31. 
10. Lou G, Chen J, Xia Y. Effects of low-dose aspirin in subjects with dyslipidemia. Lipids 
in Health and Disease. 2016 Jun 16; 15(1):106. 
11. Southern African HIV Clinicians Society. National consolidated guidelines for the 
prevention of mother to child transmission of HIV and the management of HIV in 
children, adolescents and adults. National department of health.2015; 73. Available 
from:http://www.sahivsoc.org/Files/ART%20Guidelines%2015052015.pdf. [Accessed 
21 March 2017] 
12. Cantudo-Cuenca MR, Jiménez-Galán R, Almeida-González CV, Morillo-Verdugo R. 
Concurrent use of comedications reduces adherence to antiretroviral therapy among 
HIV-infected patients. Journal of Managed Care Pharmacy. 2014 Aug; 20(8):844-50. 
13. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, 
Sighinolfi L, Gori A, Suter F. One-pill once-a-day HAART: a simplification strategy 
that improves adherence and quality of life of HIV-infected subjects. Patient Prefer 
Adherence. 2010 May 13; 4:115-25. 
  40   
 
14. Mathevula HM. Factors affecting adherence to treatment in patients on chronic 
medication at Mokopane Hospital (Doctoral dissertation, University of Limpopo 
(Turfloop Campus)). 
15. Jin J, Sklar GE, Oh, VMS, Li, SC. Factors affecting therapeutic compliance: A review 
from the patient's perspective. Therapeutics and clinical risk management. 2008; 
4(1):269. 
16. DiMatteo MR, Haskard KB,Williams SL. Health beliefs, disease severity, and patient 
adherence: a meta-analysis. Medical care. 2007; 45(6):521-528. 
17. Sharif SI, Abduelkarem AR, Bustami HA, Haddad LI, Khalil DS. Trends of home drug 
storage and use in different regions across the northern United Arab Emirates. Medical 
Principles and Practice. 2010 Jul 14; 19(5):355-8. Kheir N, El Hajj MS, Wilbur K, 
Kaissi RM, Yousif A. An exploratory study on medications in Qatar homes. Drug 
Healthc Patient Saf. 2011; 3:99-106. 
18. Foroutan B, Foroutan R. Household storage of medicines and self-medication practices 
in south-east Islamic Republic of Iran/Conservation de médicaments à domicile et 
pratiques d'automédication dans le sud-est de la République islamique d'Iran. Eastern 
Mediterranean Health Journal. 2014; 20(9):547. 
19. Kheir N, El Hajj MS, Wilbur K, Kaissi RM, Yousif A. An exploratory study on 
medications in Qatar homes. Drug Healthc Patient Saf. 2011; 3:99-106. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  41   
 
CHAPTER 4 
4.1 Synthesis 
 
The value of medication therapy in the treatment of chronic diseases can only be gained in 
patients who adhere to their prescribed therapies. Medication adherence can be affected by 
numerous psychosocial factors which affect patients with Communicable and Non-
communicable diseases alike.  
This study found that adherence rates were sub-optimal for participants with communicable and 
non-communicable diseases.  Six in every ten patients in this study reported being one hundred 
percent adherent to their treatment. More than thirty seven percent of participants had sub-
optimal medication adherence, with close to sixteen percent having missed three or more days 
of their therapy in a thirty day cycle. This result concurs with international studies that have 
found 20-50% of patients do not adhere to their prescribed medications 31 but is variable when 
compared to local studies.  For example a prior private sector HAART study 15 found that only 
10.9% of participants were one hundred percent adherent to their medication. Whereas public 
sector self-reported adherence studies have found higher rates of medication adherence where 
more than 80% of participants had taken more than 95% of their medication during the last 
thirty days 24, 25. Similar to this study, participants in the HAART study were deemed non 
adherent if they missed one or more days of their therapy during the last 30 days and while 
those in the public sector studies were deemed non- adherent if they missed two days or more of 
their medication.  
Although no significant difference was found among participants with a particular disease in 
this study, participants with Hypertension alone were more adherent to their therapies than 
participants in other disease groups investigated. Participants with HIV and Dyslipidaemia were 
among the two disease groups with lowest adherence. This is in contrast to that found in the 
Mathevula study 25 where South African HIV public sector participants were the most adherent 
to their regimens compared to participants with Hypertension and Diabetes.   
Thirty percent of participants with HIV alone reported missing 3 or more days of their 
medication in the present study. This result is similar to a study conducted in Mumbai by Naik 
et al where 30% of HAART participants were non-adherent to their medication having missed a 
week of treatment 32. Poor adherence in communicable diseases like HIV is of extreme concern, 
as non-adherence leads to poor viral suppression, increased viral resistance, increased risk of 
opportunistic infections and treatment failure 28.  Methods to increase medication adherence in 
these patients should be reviewed and modified to factors that affect these patients.  
In the present study, significant factors affecting medication adherence in participants afflicted 
with HIV alone were not taking medication because it’s too expensive, not taking medication 
because they did not want anyone to see, struggling to take medication at specific times / with 
or without food and not taking medication because they did not know how to take them 
correctly. These findings correlate with those of  Emamzadeh-Fard et al 29, who found that 
factors reducing the rate of adherence in Sub-Saharan Africa were cost, patients not informing 
their spouse and family about his/her disease, patients fear of stigma and complications 
following medication regimens.  HIV patients who hide their status report greater treatment 
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interruptions as they have to take medication secretly to avoid taking them in the presence of 
others 29. Naik et al also found cost and poor medication knowledge to be factors contributing to 
poor adherence rates in their study as 75% of patients reported the cost of HAART to be the 
greatest obstacle to adherence. Patients who understood their medication and how to use them 
were more adherent to their therapies than patients who did not32.   
In this study participants afflicted with multiple diseases were more adherent to their therapies 
than participants with single diseases. The low number of participants with HIV and 
Dyslipidaemia have to be considered when interpreting the above. Participants in these two 
groupings were the least adherent to their regimens. The study also found that participants with 
single diseases were more likely to stop their therapy when they felt better compared to 
participants with multiple diseases.  Jin 33 et al and DiMatteo 34 et al have proposed that greater 
disease severity is attributed to better compliance. This may be the case in this study as patients 
may perceive themselves as being at a higher risk of having more chronic illnesses and may 
thus have better compliance than those with single diseases.  
The relationship between age group and number of days of missed medication in this study was 
found to be significant having a spearman’s rho correlation of -0.181.A high rate of non-
adherence was found in the group of participants aged 41-50 years old, who missed 3 or more 
days of their medication. While those 70 years and above were the most adherent. This is 
consistent with systematic reviews conducted by Jin et al and Erickson et al who proposed that 
increasing age was a significant predictor of an increased likelihood of being adherent to 
medication therapies such as statins, antihypertensives, and antidiabetics. 33, 35  
As mentioned earlier the full benefits of medication therapy can only be achieved in patients 
with optimal adherence, however patients experience various obstacles that prevent them from 
adhering entirely to their regimens. Common reasons recognised for poor adherence in this 
study , were similar to those found in numerous other studies 14,15,16,33 , such as forgetting to take 
medication, running out of medication, stopping medication because it made them feel worse or 
gave a side effect and having difficulty sticking to time schedules or having medication as 
prescribed with/without food. The effect of these factors on medication adherence can be 
reduced by individualising patient regimens to suit patients’ lifestyles and minimising known 
side effects of drugs. Technology such as short message service’s or apps on cell phones can be 
used as reminders to take medication daily or pick up medication refills.  Dosage simplification 
has been found to be effective in increasing medication adherence rates 29 where practitioners 
prescribe regimens that require the lowest dosing frequency and are least complex to administer.   
Although majority of participants felt that it is important to take their medication exactly as 
prescribed by their doctor, more than one fourth of participants felt that skipping a few doses of 
their medication would not make a difference to their health. Jin et al 33 have found that 
patients’ understanding about their disease and treatment may not always be optimal. Some 
patients may not understand the effect medication therapies play in their treatment while some 
patients lack knowledge about their disease and the consequences of poor compliance. Some 
patients may be under the impression that the need for the medication prescribed was 
intermittent, thus stopping their medication presumptively. These factors need to be addressed 
by health care physicians during routine check-ups and at pharmacy visits for refills.  
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Family support has been shown to positively affect adherence. Although almost all participants 
stated that their family knew about the medication they take, only 75% stated that their family 
helps them remember to take their medication. Greater effort may need to be placed on 
involving family members in therapy regimens for patients as the risk of nonadherence has been 
stated to be 1.35 times higher in patients who do not receive emotional support 36. Social 
support has been identified as a stress buffer, which helps change emotional states, increase self-
efficacy, and influence change in adverse health behaviours 37.  
Self-medication usage was evident in this study, although less than 10% of participants admitted 
to using this type of therapy to manage their diseases. This varies with high rates of 
complementary and alternative medication (CAM) usage that was found in two studies, one 
conducted during 2008 in KZN, South Africa 38 and the other conducted during 2002 in the 
United States 39. Menton and Van Schoor 40 stated that patients are becoming more responsible 
and independent for their own health care, especially with regards to the CAM medication they 
use over the counter. When practised correctly, self-medication can offer savings for patients 
and the healthcare system. Prospective studies need to investigate patients’ self-medication 
usage and knowledge of such use by their GPs more comprehensively. Determination of the 
effect CAMs have on therapeutic outcomes also need to be investigated. 
With regards to medications used to treat communicable and non-communicable diseases in the 
private health care sector, similar patterns of prescribing corresponding to treatment guidelines 
is evident. This was contrary to results found by Steyn et al 26 in 1998, where prescribing 
patterns were more erratic, consisted of more expensive and irrational drugs and did not follow 
treatment guidelines. Biguanides and Sulphonylureas remain the most common prescribed 
therapies for patients with Type 2 Diabetes. This is similar to guidelines sets by the Society of 
Endocrinology, Metabolism and Diabetes of South Africa in 2012 41, where metformin is the 
drug of choice for monotherapy in type 2 diabetics and sulphonylureas the drug of choice for 
monotherapy in patients intolerant to the effects of metformin . Participants afflicted with 
hypertension were most commonly prescribed a diuretic, combination drug, Angiotensin 
Converting Enzyme (ACE) inhibitor or Calcium channel blocker. This is also consistent with 
practice guidelines outlined by the Southern African Hypertension Society in 2014 42,  where 
first-line drug therapy for uncomplicated hypertension comprises of low-dose thiazide-like 
diuretics, calcium channel blockers or an ACE inhibitor /Angiotensin Receptor Blocker (ARB). 
Combination therapy should be considered first line in patients where blood pressure 
measurements are above 20/10 mmHg of the goal.  Similarly the drug of choice for patients 
afflicted with dyslipidaemia was a statin, indicated by dyslipidaemia guidelines set by the South 
African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern 
Africa (LASSA) 43. With regards to HIV, FDCs were the most prevalent medicines used. This is 
in accordance with guidelines issued by the HIV clinicians’ society in 2015 44. 
Popular storage areas for medication at home remain the bedroom and the kitchen as seen in the 
results of this study. This is similar to results found in numerous Middle Eastern studies 45, 46, 47 
on home medication storage, where the bedroom, refrigerator and kitchen were the most 
frequently used areas to store medication at home.  Due to the absence of medication storage 
studies in South Africa, future studies should be conducted to elucidate more information on 
this topic. Storage areas play an important role in the integrity of medications which can be 
degraded faster by humidity or high temperatures 45. 
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4.2 Limitations 
The rate of adherence was measured categorically as the number of days missed in a 30 day 
cycle and not individually. In this study the sample population consisted of a minority of 
patients afflicted with dyslipidaemia and HIV. A larger population of study participants afflicted 
with these diseases would have contributed to more concrete findings with respect to 
determining patterns of medication adherence. However the GPs and researcher had no control 
over which type of patient would be receiving care on any particular day during the study 
period. 
 
4.3 Recommendations  
Further research needs to be conducted to determine if age is a significant predictor of 
adherence. The stigma of taking HIV medication seems to still be a prevalent issue affecting 
private sector patients with HIV/AIDS. This along with the cost of therapy and understanding 
how their medication works and how to take them correctly need to be addressed when deciding 
to treat. Future studies investigating chronic medication adherence should focus on information 
as to which drugs patients leave out intentionally and why. Identifying and addressing these 
issues during routine check-ups may improve therapeutic outcomes. Patients concerns regarding 
particular medications can be addressed, so that patients do not deliberately take medication 
holidays. Patients’ understanding and knowledge of correct medication storage areas should 
also be a focus area for prospective studies. Certain storage areas in households have higher 
humidity or temperature rates, which may accelerate medication degradation. Patients’ self-
medication usage and the effect of such on therapeutic outcomes should be investigated. Drugs 
interactions may exist between such products affecting therapeutic outcomes and exacerbating 
medication side effects.  
 
 
  
4.4 Conclusions 
This study found that participants afflicted with communicable and non-communicable diseases 
in the private health care sector have sub-optimal medication adherence. Although no 
significant correlations were found between having a particular disease and adherence, 
participants afflicted with HIV and Dyslipidaemia alone where the least adherent to their 
medication. Patients in the private sector are prescribed medication that abide to treatment 
guidelines. Self-medication usage in private sector patients is evident. Patients with HIV still 
struggle with factors such as cost of their medication, taking their medication at particular times 
and having to take their medication covertly so people do not see. Age was proposed to be a 
predictor of adherence in this study. Reasons for non-adherence include cost, forgetting to take 
medication, running out of medication, stopping medication because it made them feel worse or 
gave a side effect and having difficulty sticking to time schedules or having medication as 
prescribed with/without food. The use of generics, technology, dosage individualisation and 
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dosage simplification may aid to improve adherence. The stigma attached to being diagnosed 
with HIV is still evident and needs to be addressed on a social level.   
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Appendix 1: Survey Questionnaire 
 
Investigation of the Medication Adherence Behaviour of private sector patients with 
Communicable and Non-communicable diseases.  
Principal investigator: Kooveshni Suklal 
 
Patient Medication adherence Survey 
Demographic details 
Patient no :  
Age  
 18-30 
 31-40 
 41-50 
 51-60 
 61-70 
 71-80 
 81-90 
 91-100 
  
Gender  
 Male  
 Female  
 Other  
  
Race  African  
 Asian  
 Coloured  
 Caucasian  
 Other , please specify  
  
Highest level of Education completed  
 Primary education  
 Secondary education 
 Tertiary education  
 None  
  
Chronic disease  
 Type 2 Diabetes 
 Hypertension  
 Dyslipidaemia  
 HIV 
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  Medication regimen   
 Type 2 Diabetes Medication   Hypertension Medication 
    
 Biguanides    Diuretics 
 Sulfonylureas  Beta-blockers 
 Meglitinide derivatives ACE inhibitors 
 Alpha-glucosidase inhibitors Angiotensin II receptor blockers 
 Thiazolidinediones  Calcium channel blockers 
 GLP-1 agonists Alpha blockers 
 DPP-4 Inhibitors Central agonists 
Combination drug Combined alpha and beta-blockers 
 Insulins Direct vasodilators 
  Fixed dose combination  
   
Dyslipidaemia medication   HIV medication 
   
Statin   NNRTI 
Fibrate  NRTI 
Niacin   PI 
Bile acid resin / Bile acid 
Sequestrants 
 Co-Trimoxazole  
 
Aspirin  FDC 
 
Self – Medication 
  
Herbal / Homeopathic medication  Ayurveda Medicine  
Over the counter medication  Other , Please Specify 
Traditional medicines   
  
 Adherence behaviour  
1. Do you stop taking your medication 
when you feel better or normal? 
      Yes                             No  
2. Have you ever stopped taking your 
medication because it made you feel 
worse because of a side effect? 
      Yes                             No  
3. Have you not taken prescribed 
medication because you felt you did 
not need it? 
      Yes                             No  
4. Do you feel skipping a few doses of 
your medication will not make a 
difference? 
      Yes                             No  
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5. Have you ever not taken medication 
because it was too expensive to buy 
it? 
      Yes                             No  
6. Do you think it is important to take 
your medication exactly as 
prescribed by your doctor? 
      Yes                             No  
7. Do you sometimes forget to take 
your medication by mistake? 
      Yes                             No  
8. Have you ever not taken your 
medication because you forgot to 
pick up a refill? 
      Yes                             No  
9. Have you ever not taken your 
medication because it ran out? 
      Yes                             No  
10. Do you ever forget to take your 
medication with you when you travel 
away from home? 
      Yes                             No  
11. Have you ever not taken your 
medication because you did not want 
anyone to see? 
      Yes                             No  
12. Do your family or spouse know 
about the medication you take? 
      Yes                             No  
13. Do your family or spouse help you 
remember to take your medication? 
      Yes                             No  
14. Do you feel you get enough support 
from your family to help manage 
your disease? 
      Yes                             No  
15. Do you struggle with taking your 
medication as prescribed by your 
doctor? For example: With meals , at 
a specific time 
      Yes                             No  
16. Do you ever leave out pills because 
you feel they are too many? 
      Yes                             No  
17. Do you ever leave out pills because 
you feel they are too strong? 
      Yes                             No  
18. Did you ever not take your 
medication because you did not 
understand how to take them or use 
them correctly? 
      Yes                             No  
19. Where do you keep your 
medication? 
Kitchen             
Bathroom           
Bedroom            
Handbag            
Refrigerator     
Other  Please Specify            
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20. During the last 30 days how many 
days of your medication have you 
not taken?  
 
              0              1 – 2    3 or 
more       
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Appendix 2:  BREC Approval Letter 
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Appendix 3: Doctors information sheet and consent form 
Doctors Information Sheet and Consent to Participate in Research 
 
18 October 
2016 
Dear Doctor 
 
My name is Kooveshni Suklal. I am a researcher from the University of Kwa-Zulu Natal, 
Discipline of Pharmaceutical Sciences, School of Health Science and I am currently conducting 
research towards a Masters in Pharmacy Degree.  My contact details are as follows: 
Cell: 0734202003, Fax: 031 4612702 and Email: kooveshni@yahoo.com. 
 
You are being invited to consider participating in a study that entails the investigation of 
medication adherence in the eThekwini Metro. The aim and purpose of this research is to 
investigate the medication adherence behaviour of patients with Communicable and Non-
Communicable diseases in the private health care sector of eThekwini. Medication adherence is 
defined as the extent to which patients take medication as prescribed by their health care 
professional with respect to timing, dosage and frequency. For the purpose of this study 
Medication Adherence will be calculated using the number of days of missed doses.  
The study is expected to enrol a total of 232 patients, and will comprise of patients from each of 
the following disease groups: HIV, Type 2 Diabetes, Hypertension and Dyslipidaemia. The 
study will involve the random selection of patients, from various private practitioners’ offices in 
the eThekwini Metro, who are afflicted with one of the above diseases. Patients will be 
contacted at point of care and informed of the study. Those who volunteer to participate will be 
asked to partake in a survey to determine their adherence behaviour. The expected duration of 
the survey is 15 minutes per patient. It is hoped that data collection will be completed in a 
month. It is hoped that the study will create the following benefits for the participants: 
 Promote patient self-reflection on their current medication adherence behavior. 
 Identify problems hindering medication adherence 
 Assist in the dissemination of information on Medication adherence which could be 
used to improve patient outcomes. 
 
This study has been ethically reviewed and approved by the UKZN Biomedical research Ethics 
Committee (approval number BFC307/16).  If you choose to participate in this study, you will 
be consenting to the researcher interacting with your patients at your consultation office. Your 
details and the details of your patients will remain strictly confidential and will only be known 
to me, the researcher. Each patient enrolled in the study will be given a number and will be 
referred to using the numbers allocated. Only myself, the researcher will have access to the 
information during this study and after the necessary information has been gathered, the 
unprocessed data will be locked away and destroyed after 5 years. 
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In the event of any problems or concerns/questions you may contact me at 0734202003 / 
kooveshni@yahoo.com or the UKZN Biomedical Research Ethics Committee, contact details as 
follows: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
Supervisor 
Dr P.Naidoo 
Cell: 0839645429 
naidoopj@ukzn.ac.za 
 
Please take note that you and your patients are not obliged in any manner to participate in this 
study and may choose to withdraw from the study at any point with no consequence. 
------------------------------------------------------------------------------------------------------------------
CONSENT 
 
I, Dr _______________________________have been informed about the study entitled 
Investigation of the Medication Adherence Behaviour of private sector patients with 
Communicable and Non-communicable diseases by Kooveshni Suklal. 
 
I understand the purpose and procedures of the study. I understand that by consenting to 
participate, I am giving my permission to the researcher to have access to survey patients at my 
consultation practice. I understand that the researcher will randomly survey patients at my 
consultation offices on a date and time agreed upon by both myself and the researcher. Patients 
will be surveyed only after the patient has agreed to voluntarily participate. I agree that I have 
been given an opportunity to answer questions about the study and have had answers to my 
satisfaction. 
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I declare that my participation in this study is entirely voluntary and that I or my patients may 
withdraw at any time with no consequence. 
 
If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher at 0734202003 / kooveshni@yahoo.com. If I have any questions or 
concerns about my rights as a study participant, or if I am concerned about an aspect of the 
study or the researchers then I may contact: 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
 
____________________      ____________________ 
Signature of Participant                            Date 
 
____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable) 
 
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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Appendix 4: Patient information sheet and consent form 
Patient Information Sheet and Consent to Participate in Research towards a Masters in 
Pharmacy Degree 
18 October 
2016 
 
Dear Sir or Madam 
 
My name is Kooveshni Suklal. I am a researcher from the Discipline of Pharmaceutical 
Sciences, School of Health Science at the University of Kwa Zulu Natal, and I am currently 
conducting research towards a Masters in Pharmacy Degree.  My contact details are as follows: 
Cell: 0734202003, fax: 031 4612702 and email: kooveshni@yahoo.com. 
 
You are being invited to consider participating in a study that involves the investigation of 
medication adherence in the eThekwini Municipality. The aim and purpose of this research is to 
investigate the medication adherence behaviour of patients with Communicable and Non-
Communicable diseases in the private health care sector of eThekwini. Medication adherence is 
defined as the extent to which patients take medication as prescribed by their health care 
professional with respect to timing, dosage and frequency. For the purpose of this study 
Medication Adherence will be calculated using the number of days of missed doses.  
 
The study is expected to enroll a total of 232 patients who are being treated in the private health 
care sector of eThekwini Metro.  This group will comprise of patients who have type 2 Diabetes, 
hypertension, high blood cholesterol and HIV. The study will involve you answering a 
questionnaire administered by myself, the researcher, regarding your treatment. The duration of 
your participation if you choose to enroll is 15 minutes, which is the estimated time needed to 
answer the questionnaire. 
It is hoped that the study will create the following benefits for you:  
 Make you rethink your current medication usage behavior 
 Identify concerns that impede your complete adherence to your regimen. 
 Assist in the provision of information on Medication Adherence which could be used to 
improve outcomes in patients with Communicable and Non-communicable diseases. 
 
You are not obliged in any manner to participate in this study and you may choose to withdraw 
from the study at any point with no penalty to you. This study has been ethically reviewed and 
approved by the UKZN Biomedical research Ethics Committee (approval number 
BFC307/16).Your details will remain strictly confidential and will only be known to me the 
researcher. Each patient enrolled will be given a number and will be referred to using the numbers 
allocated. Only the researcher will have access to the information during this study and after the 
necessary information has been gathered, the unprocessed data will be kept locked away and 
destroyed after 5 years.  
 
In the event of any problems or concerns/questions you may contact the researcher at 0734202003 
/ kooveshni@yahoo.com or the UKZN Biomedical Research Ethics Committee, contact details 
as follows:  
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BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
Supervisor 
Dr P.Naidoo 
Cell: 0839645429 
naidoopj@ukzn.ac.za 
-------------------------------------------------------------------------------------------------------------- 
CONSENT 
 
I _________________________________ have been informed about the study entitled 
Investigation of the Medication Adherence Behaviour of private sector patients with 
Communicable and Non-communicable diseases by Kooveshni Suklal. 
I understand the purpose and procedures of the study. I understand that I will be asked questions 
regarding my disease, medication regimens, factors that may influence my medication 
adherence and the number of missed days of medication. I have been given an opportunity to 
answer questions about the study and have had answers to my satisfaction. I declare that my 
participation in this study is entirely voluntary and understand that I may withdraw at any time 
without affecting any treatment or care that I would usually be entitled to. 
 
If I have any further questions/concerns or queries related to the study I understand that I may 
contact the researcher at kooveshni@yahoo.com or 0734202003.If I have any questions or 
concerns about my rights as a study participant, or if I am concerned about an aspect of the study 
or the researchers then I may contact: 
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATIO 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za  
 
____________________      ____________________ 
Signature of Participant                            Date 
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____________________   _____________________ 
Signature of Witness                                Date 
(Where applicable)      
____________________   _____________________ 
Signature of Translator                            Date 
(Where applicable) 
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Appendix 5: TREE certificates 
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